Glaukos Reports Record Sales and Improved Margins: Revenue Guidance Raised for 2025 and 2026
38% Year-Over-Year Revenue Surge and Margin Gains Mark a Standout Quarter
Glaukos Corporation (NYSE:GKOS) delivered a record third quarter, with net sales of $133.54 million—up 38% year-over-year. The growth was powered by standout performance in its glaucoma business and rapid expansion in the U.S. market, underscoring the success of the company’s strategic initiatives and commercial execution.
Gross margins also ticked higher, reaching 78% on a GAAP basis and 84% on a non-GAAP basis for the quarter. These figures mark an improvement from last year’s already healthy margin profile, indicating efficiency gains and improved sales mix. CEO Thomas Burns emphasized the momentum, attributing it to a robust pipeline and global expansion efforts.
Glaucoma and U.S. Sales Highlight Exceptional Operational Execution
The quarter’s most eye-catching figure comes from Glaukos’ glaucoma segment, which hit $110.2 million in sales, a 45% jump year-over-year. U.S. glaucoma sales rose 57% to $80.8 million—signaling strong physician adoption of innovative treatments like the iDose® TR and the continued demand for MIGS devices.
| Metric | Q3 2025 | Q3 2024 | Year-Over-Year Change |
|---|---|---|---|
| Total Net Sales | $133.54M | $96.67M | +38% |
| Glaucoma Net Sales | $110.20M | $75.93M | +45% |
| U.S. Glaucoma Net Sales | $80.80M | $51.49M | +57% |
| GAAP Gross Margin | 78% | 77% | +1 pp |
| Non-GAAP Gross Margin | 84% | 82% | +2 pp |
| Net Loss | ($16.23M) | ($21.41M) | Lower loss |
| Cash, Equivalents & Short-Term Investments | $277.55M | N/A | - |
Financial Resilience Strengthened: Operating Loss Narrows, Balance Sheet Solidifies
Operating efficiency improved as both GAAP and non-GAAP operating losses narrowed sharply from the prior year. On a GAAP basis, loss from operations shrank to $16.37 million (from $24.66 million). Non-GAAP loss was trimmed to $9.30 million from $18.43 million in Q3 2024. Net loss per share improved to ($0.28) from ($0.39), with non-GAAP per share loss narrowing to ($0.16).
The company closed the quarter with $277.55 million in cash, short-term investments, and restricted cash—and reported zero debt, supporting continued investment in innovation and strategic expansion without balance sheet stress.
Revenue Guidance Raised as Innovation Drives Future Ambitions
In light of robust sales trends, Glaukos raised its 2025 revenue guidance to $490–$495 million (previously $480–$486 million) and issued a preliminary 2026 sales target of $600–$620 million. The increased outlook reflects confidence in new launches, particularly for novel therapies in glaucoma and corneal disease, and anticipated momentum in core platforms.
Burns cited continued development of “dropless” platforms and strong adoption across the physician community as reasons for the company’s elevated targets and upbeat tone. The strong performance in both the U.S. and international glaucoma markets is a key pillar in these expectations.
Key Financial Metrics for Q3 2025
| Metric | Q3 2025 | Q3 2024 |
|---|---|---|
| SG&A Expenses (GAAP) | $83.00M | $64.00M |
| R&D Expenses (GAAP) | $38.07M | $34.75M |
| Non-GAAP Operating Loss | ($9.30M) | ($18.43M) |
| Non-GAAP Net Loss Per Share | ($0.16) | ($0.28) |
Takeaway: Strategic Investments Pay Off Amid Pipeline Momentum
Glaukos’ results highlight the pay-off from investments in innovative therapies and international expansion. Despite continued R&D and SG&A growth to support its robust pipeline, the company’s improving gross margins, shrinking losses, and debt-free position present a positive long-term narrative.
As Glaukos boosts its sales guidance for 2025 and lays out an even bolder forecast for 2026, investors may want to watch upcoming launches and regulatory milestones—particularly for its novel “dropless” drug delivery systems—as key drivers for continued performance. Financial resilience and operational execution seem to set a foundation for potential outperformance as the pipeline matures.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI